ArticleNuclear medicine communications2018
A retrospective study of the clinical features in papillary thyroid microcarcinoma depending on age.
Article in Nuclear medicine communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Positive preoperative circulating tumor cells level associated with lymph node metastasis in papillary thyroid carcinoma patients with capsular invasion.World journal of surgical oncology · 2025Article
- A retrospective study of the risk factors and the prognosis in patients with papillary thyroid carcinoma depending on the number of lymph node metastasis.Clinical and experimental medicine · 2021Article
- Predictive factors for central lymph node metastases in papillary thyroid microcarcinoma.World journal of clinical cases · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to evaluate the clinical features and correlation of neck lymph node involvement of papillary thyroid microcarcinoma (PTMC) according to patients' age. We divided the patients into three groups according to age: young group (<45 years, n=83), middle group (45-54 years, n=80), and old group (≥55 years, n=53). The clinical features among the different groups were analyzed retrospectively. All of the 216 patients had received radioiodine ablation at least one time. Among these, 84 patients had central lymph node metastasis (CLNM), 11 patients had lateral lymph node metastasis (LLNM), and 26 patients had both CLNM and LLNM. We show that both lymph node metastasis (LNM) and the CLNM rate were significantly higher in young patients compared with old patients (P=0.000 and 0.000, separately). The radioactive iodine curative ratio in younger patients is also lower than that in the other two groups (37.35, 18.75, and 32.08%, separately, P=0.029). Further Bonferroni test among three groups identified that both LNM and the CLNM rate were significantly higher in the young group than in the old group (P=0.000 and 0.000, separately). Logistic regression analysis showed that young [odds ratio (OR): 2.087, 95% confidence interval (CI): 1.013-4.299, P=0.046] and middle age (OR: 4.049, 95% CI: 1.933-8.482, P=0.000), and extrathyroid extension (OR: 1.952, 95% CI: 1.027-3.711, P=0.041) are independent risk factors for neck LNM. Unlike LNM, young age (<45 years) (OR: 3.667, 95% CI: 1.732-7.761, P=0.001), extrathyroid extension (OR: 2.256, 95% CI: 1.189-4.282, P=0.013), and male sex (OR: 2.057, 95% CI: 1.042-4.061, P=0.038) were found to be independent risk factors for CLNM. However, no independent risk factors were found to be associated with LLNM. The patients with PTMCs had different clinical features according to age. PTMCs in young patients were more aggressive, especially in LNM. Hence, clinicians should consider an individualized treatment according to age in younger patients to achieve better therapeutic efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.